Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 7.83
- Piotroski Score 6.00
- Grade N/A
- Symbol (EGF)
- Company BlackRock Enhanced Government Fund, Inc.
- Price $10.02
- Changes Percentage (-0.5%)
- Change -$0.05
- Day Low $10.02
- Day High $10.10
- Year High $11.51
BlackRock Enhanced Government Fund, Inc. is a closed-ended fixed income mutual fund launched by BlackRock, Inc. It is managed by BlackRock Advisors, LLC. The fund invests in fixed income markets. It primarily invests in a portfolio of United States government and government agency securities, including the U.S. government mortgage-backed securities. The fund invests in non U.S. government debt securities of foreign or domestic issuers, including commercial paper, notes, corporate bonds, debentures, asset-backed securities, mortgage-backed securities, corporate loans, sovereign debt securities, and money market securities. It was formerly known as Enhanced Government Fund, Inc. BlackRock Enhanced Government Fund, Inc. was formed in 2006 and is domiciled in United States.
- Last Earnings 09/12/2024
- Ex-Dividend for 5/16 Dividend 10/15/2024
- Dividend Payable 10/31/2024
- Today N/A
- Next Earnings (Estimated) N/A
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.45
- Trailing P/E Ratio 20.68
- Forward P/E Ratio 20.68
- P/E Growth 20.68
- Net Income $1.63 M
Income Statement
Quarterly
Annual
Latest News of EGF
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer
The FDA approved RYBREVANT in combination with chemotherapy for EGFR-mutated NSCLC patients. Results from the Phase 3 MARIPOSA-2 study showed improved outcomes, making it the third new indication for ...
By Yahoo! Finance | 2 weeks ago -
Retail investors who hold 46% of Siegfried Holding AG (VTX:SFZN) gained 3.9%, institutions profited as well
Retail investors own 46% of Siegfried Holding AG, making them the most powerful group. Despite a recent stock price increase, institutions with 43% ownership also stand to gain. Analyzing shareholder ...
By Yahoo! Finance | 2 weeks ago -
RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer
Johnson & Johnson announced positive results from the Phase 3 MARIPOSA-2 study, showing RYBREVANT combined with chemotherapy led to significant and sustained improvement in post-progression outcomes f...
By Yahoo! Finance | 3 weeks ago